Biontech Se ADR (BNTX)

$91.46 -0.14 (-0.15%)
Market Cap 20.63B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 1,403,600
Avg Vol 1,008,300
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 4%
Beta 1.30
Analysts Strong Sell
Price Target $137.68

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
nashyy7
nashyy7 Dec. 19 at 1:56 PM
$BNTX vaccine biotech in mid range, next big move likely waits on a fresh data or pipeline headline with serious volume
0 · Reply
taxplanr
taxplanr Dec. 19 at 1:16 PM
$PFE $BNTX $MRNA
0 · Reply
BrendaGarrett356
BrendaGarrett356 Dec. 19 at 12:40 PM
$BNTX Pipeline progress reinforcing BioNTech as more than a single cycle story
0 · Reply
taxplanr
taxplanr Dec. 19 at 11:39 AM
$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure ​on top of $CVAC losses
0 · Reply
SenefAS
SenefAS Dec. 19 at 7:23 AM
Today upgrade for Genmab $GMAB $GMAB.CO of Deutsche Bank for a buy with a new target of 2400 DK… Still partnership with Pfizer,Abbvie,BioNTech $PFE $ABBV $BNTX $NVS
0 · Reply
stockpro27
stockpro27 Dec. 19 at 2:15 AM
$BNTX $CADL $PFE biotech stocks are like lotto tickets. They can make or break you. I have been on both sides. I recently did well with GPCR when they announced phase 2 results for their weight loss drug.
1 · Reply
CAN_2409
CAN_2409 Dec. 19 at 2:09 AM
$CADL i made $47,500. In one day in 2020 with $BNTX on a deal with $PFE I learned I should have held instead of penny flipping! This is farr more valuable than a Covid Vax that altered DNA to create more super Cancers for them to cure with CAN-2409. Please read what the richest Oncologist's has said about that. Dr. Patrick S... LOAD!
0 · Reply
TreasureBoyX
TreasureBoyX Dec. 18 at 10:08 PM
Does anyone remember OCTO / QMMM or ZJYL? JLHL could potentially be the next china crime squeezer. JLHL has one ONE single watcher on Stocktwits and fits perfectly into the Hong Kong gangster ramp and dump scheme. JLHL has about 1 mil float and IPO'd in 2025. Put it on watchlist thank me later. $SAVA $OCGN $BNTX $SPY $IWM to JLHL!
1 · Reply
ChangeisNewConstant
ChangeisNewConstant Dec. 18 at 6:28 PM
$BNTX will there be any upcoming catalyst which can drive this stock upwards or it will hang here forever
1 · Reply
prismmarketview
prismmarketview Dec. 18 at 4:58 PM
BioNTech (NASDAQ: $BNTX) has closed its roughly $1.25 billion all‑stock acquisition of CureVac, bringing in CureVac’s mRNA design, LNP delivery, and manufacturing assets to deepen BioNTech’s oncology‑focused mRNA platform, with 86.75% of CureVac shares already tendered and full squeeze‑out of the remainder expected in early 2026. https://prismmarketview.com/biontech-completes-curevac-acquisition-expanding-its-mrna-platform/
1 · Reply
Latest News on BNTX
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 1 day ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 5:54 PM EST - 9 days ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 10 days ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 12 days ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 15 days ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 17 days ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 17 days ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 23 days ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 4 weeks ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 5 weeks ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 5 weeks ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 5 weeks ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 6 weeks ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 6 weeks ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 6 weeks ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 6 weeks ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 6 weeks ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 7 weeks ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 7 weeks ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 2 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 2 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 2 months ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 3 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 3 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 3 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 3 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 3 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 3 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 3 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 3 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 3 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 4 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 4 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 4 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 1:56 PM EDT - 4 months ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 4 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 4 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 4 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 4 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Aug 1, 2025, 4:51 PM EDT - 4 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 5 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 5 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Aug 1, 2025, 5:59 AM EDT - 5 months ago

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

MRNA PFE

Pandemic darlings Moderna, BioNTech are now on two different paths

Jul 31, 2025, 7:00 AM EDT - 5 months ago

Pandemic darlings Moderna, BioNTech are now on two different paths

MRNA

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 5 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 5 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

PFE

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

Jul 23, 2025, 4:11 AM EDT - 5 months ago

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

PFE

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

Jul 21, 2025, 6:45 AM EDT - 5 months ago

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board

Jul 17, 2025, 8:30 AM EDT - 5 months ago

BioNTech Announces Ryan Richardson to Step Down from the Management Board

nashyy7
nashyy7 Dec. 19 at 1:56 PM
$BNTX vaccine biotech in mid range, next big move likely waits on a fresh data or pipeline headline with serious volume
0 · Reply
taxplanr
taxplanr Dec. 19 at 1:16 PM
$PFE $BNTX $MRNA
0 · Reply
BrendaGarrett356
BrendaGarrett356 Dec. 19 at 12:40 PM
$BNTX Pipeline progress reinforcing BioNTech as more than a single cycle story
0 · Reply
taxplanr
taxplanr Dec. 19 at 11:39 AM
$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure ​on top of $CVAC losses
0 · Reply
SenefAS
SenefAS Dec. 19 at 7:23 AM
Today upgrade for Genmab $GMAB $GMAB.CO of Deutsche Bank for a buy with a new target of 2400 DK… Still partnership with Pfizer,Abbvie,BioNTech $PFE $ABBV $BNTX $NVS
0 · Reply
stockpro27
stockpro27 Dec. 19 at 2:15 AM
$BNTX $CADL $PFE biotech stocks are like lotto tickets. They can make or break you. I have been on both sides. I recently did well with GPCR when they announced phase 2 results for their weight loss drug.
1 · Reply
CAN_2409
CAN_2409 Dec. 19 at 2:09 AM
$CADL i made $47,500. In one day in 2020 with $BNTX on a deal with $PFE I learned I should have held instead of penny flipping! This is farr more valuable than a Covid Vax that altered DNA to create more super Cancers for them to cure with CAN-2409. Please read what the richest Oncologist's has said about that. Dr. Patrick S... LOAD!
0 · Reply
TreasureBoyX
TreasureBoyX Dec. 18 at 10:08 PM
Does anyone remember OCTO / QMMM or ZJYL? JLHL could potentially be the next china crime squeezer. JLHL has one ONE single watcher on Stocktwits and fits perfectly into the Hong Kong gangster ramp and dump scheme. JLHL has about 1 mil float and IPO'd in 2025. Put it on watchlist thank me later. $SAVA $OCGN $BNTX $SPY $IWM to JLHL!
1 · Reply
ChangeisNewConstant
ChangeisNewConstant Dec. 18 at 6:28 PM
$BNTX will there be any upcoming catalyst which can drive this stock upwards or it will hang here forever
1 · Reply
prismmarketview
prismmarketview Dec. 18 at 4:58 PM
BioNTech (NASDAQ: $BNTX) has closed its roughly $1.25 billion all‑stock acquisition of CureVac, bringing in CureVac’s mRNA design, LNP delivery, and manufacturing assets to deepen BioNTech’s oncology‑focused mRNA platform, with 86.75% of CureVac shares already tendered and full squeeze‑out of the remainder expected in early 2026. https://prismmarketview.com/biontech-completes-curevac-acquisition-expanding-its-mrna-platform/
1 · Reply
10xStacks
10xStacks Dec. 17 at 7:58 PM
$OCGN ohhhh those days proving that the mRNA crap was garbage by $PFE $BNTX $MRNA - finally mainstream caught up https://www.cnn.com/2025/12/12/health/fda-black-box-warning-covid-vaccine
1 · Reply
DrSammy
DrSammy Dec. 17 at 7:19 PM
$BNTX
0 · Reply
ting2023
ting2023 Dec. 17 at 7:05 PM
$BNTX Bye cancer! Yeah Baby
0 · Reply
taxplanr
taxplanr Dec. 17 at 3:20 PM
Small cell lung cancer being beat again by Ivermectin and Mebendazole $BNTX No level 3 side effects https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-2d7?utm_source=post-email-title&publication_id=1385328&post_id=181879102&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Dec. 17 at 3:15 PM
Ivermectin Mebendazole and CBD Oil beating cancer $BNTX Did you know Cannabis Oil works on the same ACE-2 receptor the nano lipids from malignantRNA uses but better since God made them? https://makisw.substack.com/p/ivermectin-mebendazole-cbd-oil-mcp?utm_source=post-email-title&publication_id=1385328&post_id=181879063&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Dec. 17 at 2:04 PM
$GOVX doing better against cancer than $BNTX https://finance.yahoo.com/news/geovax-announces-british-journal-haematology-140000421.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAANlnO_-m8U9WNp8UBaNjnnOE1EEcK-P0-PdukZFjsp1T-a18FdLoSSIhObOMVzTv_wSNfFLtJYSF5RHG4rp8Ebx-jYqlUJxXQJR_MlU7cC0qXR97I1pg0p_CgYvyvcI6sT2SYy437YakYxaQF1Vh6wFltHV3IjsmhlSXtphjLgnX
0 · Reply
taxplanr
taxplanr Dec. 17 at 1:50 PM
$BNTX myocarditis is not good news
0 · Reply
BullYa
BullYa Dec. 17 at 1:17 PM
$BNTX 📉 $85 should be the bottom 👀
0 · Reply
Tom2772
Tom2772 Dec. 17 at 11:13 AM
$BNTX https://med.stanford.edu/news/all-news/2025/12/myocarditis-vaccine-covid.html Very good!
0 · Reply
Tom2772
Tom2772 Dec. 17 at 3:32 AM
$BNTX $BMY https://investors.biontech.de/news-releases/news-release-details/biontech-and-bristol-myers-squibb-present-first-global-phase-2 Sounds good!
1 · Reply
Tom2772
Tom2772 Dec. 16 at 9:31 PM
$CVAC The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for $BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than $1.25 billion in the long run.
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 8:30 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BNTX $90.00 Put · JAN 16, 2026 Exp Entry Price: $2.80 - $3.40 Exit Price Target: $6.55 Profit Margin: +134% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply